Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

AstraZeneca plc (AZN) Ordinary US$0.25

Sell:8,598.00p Buy:8,601.00p 0 Change: 4.00p (0.05%)
FTSE 100:0.62%
Market closed Prices as at close on 4 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8,598.00p
Buy:8,601.00p
Change: 4.00p (0.05%)
Market closed Prices as at close on 4 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8,598.00p
Buy:8,601.00p
Change: 4.00p (0.05%)
Market closed Prices as at close on 4 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Contact details

Address:
1 Francis Crick Avenue
CAMBRIDGE
CB2 0AA
United Kingdom
Telephone:
+44 (020) 73045000
Website:
https://www.astrazeneca.com/Home

Important dates

Future events
Interim results 30 July 2020 30/07/20
Quarter 2 results 30 July 2020 30/07/20
Past events
Quarterly results 29 April 2020 29/04/20
AGM 29 April 2020 29/04/20
Interim dividend payment date 30 March 2020 30/03/20
Interim dividend payment date 20 March 2020 20/03/20
Interim ex-dividend date 27 February 2020 27/02/20
Final results 14 February 2020 14/02/20
Quarter 3 results 24 October 2019 24/10/19
Interim dividend payment date 09 September 2019 09/09/19
Interim ex-dividend date 08 August 2019 08/08/19
Quarter 2 results 25 July 2019 25/07/19
Interim results 25 July 2019 25/07/19

General stock information

EPIC:
AZN
ISIN:
GB0009895292
Market cap:
£112.85 billion
Shares in issue:
1.31 billion
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 100,FTSE 350,FTSE All Share,FTSE techMARK All Share

Key personnel

  • Pascal Soriot
    Chief Executive Officer, Executive Director
  • Marc Dunoyer
    Chief Financial Officer, Executive Director
  • Katarina Ageborg
    Executive Vice President - Sustainability, Chief Compliance Officer
  • Fiona Cicconi
    Executive Vice President - Human Resources
  • Jose Baselga
    Executive Vice President - Research & Development Oncology
  • Pam Cheng
    Executive Vice President - Operations and Information Technology
  • Ruud Dobber
    Executive Vice President, BioPharmaceuticals Business
  • David Fredrickson
    Executive Vice President, Global Head Oncology Business Unit
  • Menelas Pangalos
    Executive Vice President - Research & Development BioPharmaceuticals
  • Iskra Reic
    Executive Vice President - Europe and Canada

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.